Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Projects/Programs

Displaying 1 - 25 of 34

RM 8376 Microbial Pathogen DNA Standards for Detection and Identification

Ongoing
RM 8376 consists of 20 individual gDNA components from 19 bacterial strains and 1 human reference genome. Its purpose is to enable developers and regulators to evaluate the analytical performance of metagenomic next generation sequencing (mNGS) tools. The material is certified for chromosomal copy

Biosecurity for Synthetic Nucleic Acid Sequences

Ongoing
Emerging biotechnology, enabled by the ability to genetically engineer biological systems similar to the way we write software and program computers, can provide solutions to many pressing societal needs related to health, food security, supply chain resilience, and job growth for economic and

Biosurveillance and Pathogen Detection

Ongoing
NIST has established partnerships with other federal agencies to develop standards and measurement solutions to support biosurveillance. These efforts are supported in part through interagency agreements with partner agencies listed below to address their standards needs. PROGRAMS Standards for

Cancer Biomarker Measurements and Collaborations

Ongoing
Collaborations and Cooperative Research Agreements We welcome collaborations and can help with assay validation and development of reference materials. Below are some examples of our collaborations and ways we can develop test materials. Early Detection Research Network (EDRN): Interagency agreement

Cancer Genome in a Bottle

Ongoing
Goals: This project is an extension of the Genome in a Bottle Consortium to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of cancer genome sequencing to clinical practice and innovations in technologies. The priority of GIAB

Cell Line Authentication

Ongoing
Cell Line Authentication – The scientific community has responded to the misidentification of human cell lines with validated methods to authenticate these cells; however, there are few assays available for nonhuman cell line identification. We have developed multiplex polymerase chain reaction (PCR

Chinese hamster ovary (CHO) cell line authentication

Ongoing
Intended impact To develop a PCR based multiplex assay that can be used to authenticate Chinese hamster ovary cell lines which are important in the production of biological therapeutics. Objectives Identify tetranucleotide STR markers by searching the CHO genome using BLAST Design and optimize a

Clinical and Forensic Reference Materials

Ongoing
Below is a listing of the reference materials currently produced by the Applied Genetics group. Clinical Diagnostics SRM 2393 - CAG Repeat Length Mutation in Huntington`s Disease SRM 2365 - BK Virus DNA Quantitative Standard SRM 2366a - Cytomegalovirus DNA (Towne Δ147 BAC) for DNA SRM 2367 - JC

Combating Antibiotic Resistance

Ongoing
We are developing in vitro systems to generate controlled chemical and community environments that mimic the features of real-world that are important determinants for evolutionary rate and resistance potential. In addition, we are developing tools to isolate and analyze single bacteria along the

Forensic Genetics

Ongoing
Since the late 1980s, NIST has had scientists involved in DNA testing (aka "DNA Fingerprinting"). Early concerns over measurement accuracy and poor quality control of forensic DNA tests caused the Department of Justice to call upon NIST scientists to help with standards development and technology

Genome in a Bottle

Ongoing
Consortium goals: The Genome in a Bottle Consortium is a public-private-academic consortium hosted by NIST to develop the technical infrastructure (reference standards, reference methods, and reference data) to enable translation of whole human genome sequencing to clinical practice and innovations

H5 Influenza Positive Controls

Ongoing
In response to the current H5N1 avian influenza outbreak, NIST has developed a research grade test material (RGTM) for PCR-based assays. This material contains 3 vials with RNA fragments for HA (Part A), NA (Part B), and MP (Part C). A NIST Reference Material is also under development. The guidance

Measuring Antimicrobial Resistance

Ongoing
Antibiotic resistance has been identified in the Nation’s Action Plan to improve the health and wellbeing of the American people. NIST scientists are leveraging a wide range of measurement capabilities to study microbial community dynamics with regard to antimicrobial resistance. Using a range of

Methods for Absolute Quantitation of Transcription

Ongoing
The ability to engineer novel, useful functions into microbial cells for manufacturing or therapeutic applications has accelerated rapidly over the last few decades. However, the measurements required to underpin predictive engineering of these systems are typically not comparable across different

Microbial Genomic Measurements

Completed
The RM 8375 is a stable and homogeneous material whose intended use is whole genome sequencing quality control and proficiency testing. The genomic DNA is intended to be analyzed in the same way as any other sample a laboratory would analyze extracted DNA, such as through the use of genome assembly

Mpox (MPXV) Synthetic DNA PCR Standards

Ongoing
A new material from NIST can aid in the evaluation and development of selected qPCR assays for the mpox virus. We are offering a unit free of charge in exchange for your feedback, which will help us improve and further develop the material. Questions? Contact MPXV-RGTM [at] nist.gov (MPXV-RGTM[at]nist[dot]gov) . NIST supports the

NIST/EDRN Cancer Biomarker Collaboration

Completed
Our lab is one of the EDRN Biomarker Reference Laboratories working with the EDRN discovery labs to improve the quality of the measurements done on new cancer biomarkers for early detection of cancer and for cancer risk. TECHNICAL APPROACH Evaluate current assays used for detection of cancer

NIST Genome Editing Consortium: Working Group 1 - Specificity Measurements

Ongoing
Genome editing technologies are able to produce DNA sequence changes of a variety of sizes and at a variety of frequencies in a population of edited cells. Having increased confidence in reliably detecting the sequences generated by a genome editing process was a need area identified. Project 1

NIST Genome Editing Consortium: Working Group 2 - Data & Metadata

Ongoing
Develop a metadata schema for genome editing experiments Develop a way of curating and entry that is low burden for user Release control data with linked metadata PROGRESS Phase1 metadata entries and templates completed In process of compiling and testing use cases, user interfaces, and

NIST Genome Editing Consortium

Ongoing
Targeted genome editing , a method used to alter the DNA of living cells at desired locations, is poised to revolutionize science and medicine. To fight diseases, novel genome edited therapeutics, including those for use in regenerative medicine and infectious diseases, are being developed. Many